Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Anesthetic Effect Overview | 9 | 1 |
| Therapeutics Development | 10 | 2 |
| Pipeline Products for Anesthetic Effect Overview | 10 | 1 |
| Pipeline Products for Anesthetic Effect Comparative Analysis | 11 | 1 |
| Anesthetic Effect Therapeutics under Development by Companies | 12 | 2 |
| Anesthetic Effect Therapeutics under Investigation by Universities/Institutes | 14 | 1 |
| Anesthetic Effect Pipeline Products Glance | 15 | 4 |
| Late Stage Products | 15 | 1 |
| Clinical Stage Products | 16 | 1 |
| Early Stage Products | 17 | 1 |
| Unknown Stage Products | 18 | 1 |
| Anesthetic Effect Products under Development by Companies | 19 | 1 |
| Anesthetic Effect Products under Investigation by Universities/Institutes | 20 | 1 |
| Anesthetic Effect Companies Involved in Therapeutics Development | 21 | 14 |
| Biolab Farmaceutica Ltda | 21 | 1 |
| Drawbridge Pharmaceuticals Pty Ltd | 22 | 1 |
| Expanesthetics Inc | 23 | 1 |
| Jiangsu Hengrui Medicine Co., Ltd. | 24 | 1 |
| Lipicard Technologies Limited | 25 | 1 |
| NanoMedex Pharmaceuticals, Inc. | 26 | 1 |
| Paion AG | 27 | 1 |
| Phosphagenics Limited | 28 | 1 |
| Physica Pharma | 29 | 1 |
| Primex Pharmaceuticals Oy | 30 | 1 |
| Proteus SA | 31 | 1 |
| Sphaera Pharma Pvt. Ltd. | 32 | 1 |
| Taiwan Liposome Company, Ltd. | 33 | 1 |
| The Medicines Company | 34 | 1 |
| Anesthetic Effect Therapeutics Assessment | 35 | 8 |
| Assessment by Monotherapy Products | 35 | 1 |
| Assessment by Target | 36 | 2 |
| Assessment by Mechanism of Action | 38 | 2 |
| Assessment by Route of Administration | 40 | 2 |
| Assessment by Molecule Type | 42 | 1 |
| Drug Profiles | 43 | 32 |
| ABP-700 Drug Profile | 43 | 2 |
| ADV-6209 Drug Profile | 45 | 1 |
| alphaxalone Drug Profile | 46 | 2 |
| bupivacaine hydrochloride Drug Profile | 48 | 1 |
| Carboetomidate Drug Profile | 49 | 1 |
| gabafol Drug Profile | 50 | 1 |
| HSK-3486 Drug Profile | 51 | 1 |
| LT-1121 Drug Profile | 52 | 1 |
| LT-1123 Drug Profile | 53 | 1 |
| Methoxycarbonyl Carboetomidate Drug Profile | 54 | 1 |
| Methoxycarbonyl Etomidate Drug Profile | 55 | 2 |
| neosaxitoxin Drug Profile | 57 | 2 |
| PB-5109 Drug Profile | 59 | 1 |
| PHY-301 Drug Profile | 60 | 1 |
| propofol Drug Profile | 61 | 1 |
| propofol Drug Profile | 62 | 1 |
| propofol microemulsion Drug Profile | 63 | 1 |
| remimazolam Drug Profile | 64 | 6 |
| remimazolam Drug Profile | 70 | 1 |
| Small Molecule for General Anesthetic Effect Drug Profile | 71 | 1 |
| Small Molecules for General Anesthetic Effect Drug Profile | 72 | 1 |
| Small Molecules to Inhibit NMDA Receptor for Anesthesia Drug Profile | 73 | 1 |
| SPR-819 Drug Profile | 74 | 1 |
| Anesthetic Effect Dormant Projects | 75 | 2 |
| Anesthetic Effect Discontinued Products | 77 | 1 |
| Anesthetic Effect Product Development Milestones | 78 | 11 |
| Featured News &Press Releases | 78 | 1 |
| Sep 06, 2016: PAION announces clinical development progress with remimazolam by its Partner Yichang Humanwell in China | 78 | 1 |
| Jun 19, 2016: Paion Reports Positive Remimazolam Headline Data In Pivotal U.S. Phase III Study In Procedural Sedation For Colonoscopy | 78 | 1 |
| Feb 18, 2016: PAION reports about positive pre-NDA meeting with Japanese authority PMDA | 79 | 1 |
| Feb 09, 2016: Paion Discontinues European Remimazolam Phase III Trial In Cardiac Surgery Patients Due To Insufficient Recruitment | 80 | 1 |
| Dec 01, 2015: PAION Announces Initiation of U.S. Clinical Safety Trial of Remimazolam in High Risk Patients Undergoing Colonoscopy | 80 | 1 |
| Oct 26, 2015: Results of First-in-Man Study with Investigational Anesthetic ABP-700 Presented at ANESTHESIOLOGY 2015 and International Society of Anesthetic Pharmacology Annual Meetings | 81 | 1 |
| Oct 22, 2015: The Medicines Company To Present Data on Potentially Innovative Surgical Anesthetic at American Society of Anesthesiologists 2015 Meeting | 82 | 1 |
| Oct 12, 2015: Remimazolam Posters at Anesthesiology 2015 | 83 | 1 |
| Aug 11, 2015: Paion Starts EU Phase III Study With Remimazolam In The Indication General Anesthesia | 83 | 1 |
| Jun 08, 2015: PAION Announces Initiation Of Second U.S. Phase 3 Clinical Trial Of Remimazolam For Procedural Sedation During Bronchoscopy | 84 | 1 |
| Feb 10, 2015: Drawbridge Pharmaceuticals granted Notice of Allowance for divisional patent in the United States | 85 | 1 |
| Nov 05, 2014: Paion's Partner Ono Decides Not To File For Regulatory Approval Of REMIMAZOLAM In Japan And Will Return Its REMIMAZOLAM Rights For Japan To Paion | 85 | 1 |
| Oct 14, 2014: Invitation To Conference Call Of Paion About The Project Status Of Remimazolam In Japan | 86 | 1 |
| Oct 10, 2014: Paion Expects Ono S Remimazolm Decision On Filing In Japan In November 2014 | 86 | 1 |
| Oct 01, 2014: Two Scientific Remimazolam Presentations Are Accepted for ASA and ACG Meeting in October 2014 | 86 | 3 |
| Appendix | 89 | 2 |
| Methodology | 89 | 1 |
| Coverage | 89 | 1 |
| Secondary Research | 89 | 1 |
| Primary Research | 89 | 1 |
| Expert Panel Validation | 89 | 1 |
| Contact Us | 89 | 1 |
| Disclaimer | 90 | 1 |
